M. Joubert

发表

Chemical Modifications in Therapeutic Protein Aggregates Generated under Different Stress Conditions

Linda O. Narhi, Randal R. Ketchem, Jette Wypych, 2011, The Journal of Biological Chemistry.

A Mass Spectrometric Characterization of Light-Induced Modifications in Therapeutic Proteins.

Zhongqi Zhang, Z. Zhou, M. Joubert, 2022, Journal of pharmaceutical sciences.

Chemical and Biophysical Characteristics of Monoclonal Antibody Solutions Containing Aggregates Formed during Metal Catalyzed Oxidation

K. Fujimori, W. Jiskoot, Q. Luo, 2017, Pharmaceutical Research.

Glycan engineering reveals interrelated effects of terminal galactose and core fucose on antibody‐dependent cell‐mediated cytotoxicity

M. Joubert, G. C. Flynn, Andrew F Shami, 2020, Biotechnology progress.

Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges.

W. Jiskoot, M. Joubert, L. Narhi, 2016, Journal of pharmaceutical sciences.

Characterization of Subvisible Particles in Biotherapeutic Pre-Filled Syringes: The Role of Polysorbate and Protein on the Formation of Silicone Oil and Protein Subvisible Particles After Drop Shock.

M. Joubert, L. Narhi, N. Joh, 2019, Journal of pharmaceutical sciences.

Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting.

D. Volkin, C. R. Middaugh, M. Joubert, 2015, Journal of pharmaceutical sciences.

Differential Influence on Antibody Dependent Cellular Phagocytosis by Different Glycoforms on Therapeutic Monoclonal Antibodies.

M. Joubert, S. Kuhns, Qingchun Zhang, 2020, Journal of biotechnology.

Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics

M. Joubert, L. Narhi, G. C. Flynn, 2016, PloS one.

A Systematic Interrogation of MHC Class I Peptide Presentation Identifies Constitutive and Compensatory Protein Degradation Pathways

David J. Sherman, Jennifer L Mamrosh, Michael J. Sweredoski, 2021, bioRxiv.

Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics.

T. Arora, M. Joubert, L. Narhi, 2013, Journal of pharmaceutical sciences.

State-of-the-art and emerging trends in analytical approaches to pharmaceutical-product commercialization.

M. Joubert, J. Wypych, C. Goudar, 2022, Current opinion in biotechnology.

Impact of Precipitation of Antibody Therapeutics After Subcutaneous Injection on Pharmacokinetics and Immunogenicity.

J. Ferbas, M. Joubert, N. Joh, 2019, Journal of pharmaceutical sciences.

Observation of Heavy-Chain C-Terminal Amidation in Human Endogenous IgG.

Ming Li, Zhongqi Zhang, M. Joubert, 2022, Journal of pharmaceutical sciences.

The manipulation of ostrich meat quality, composition and shelf life

M. Joubert, 2003 .

T-cell-dependent antibody responses in the rat: Forms and sources of keyhole limpet hemocyanin matter

J. Reindel, H. Lebrec, M. Joubert, 2014, Journal of immunotoxicology.

Measurementof the Free Alpha Subunitof Human GlycoproteinHormonesby a Monoclonal Antibody-BasedImmunoradiometricAssay , and FurtherExplorationof AntigenicSites on the ChoriogonadotropinMolecule

Robert, M. Joubert, H. Robert, 2004 .

Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses

M. Joubert, L. Narhi, B. Kerwin, 2012, The Journal of Biological Chemistry.

Immunogenicity of Therapeutic Protein Aggregates.

Marisa K Joubert, Jainik P Panchal, Elizabeth M Topp, 2016, Journal of pharmaceutical sciences.

Determination of interactions between antibody biotherapeutics and copper by size exclusion chromatography (SEC) coupled with inductively coupled plasma mass spectrometry (ICP/MS).

M. Joubert, D. Semin, Yasser Nashed-Samuel, 2019, Analytica chimica acta.

Classification and Characterization of Therapeutic Antibody Aggregates

Marisa K Joubert, Yasser Nashed-Samuel, Jette Wypych, 2011, The Journal of Biological Chemistry.

Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics

Vibha Jawa, Marisa K Joubert, Meghana Deshpande, 2016, The AAPS Journal.

Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate.

Q. Luo, M. Joubert, J. Wypych, 2016, Analytical chemistry.

Use of in vitro human skin models to assess potential immune activation in response to biotherapeutic attributes and process-related impurities.

J. Ferbas, M. Joubert, N. Joh, 2022, Journal of pharmaceutical sciences.

Silicone Oil Particles in Pre-Filled Syringes with Human Monoclonal Antibody Representative of Real-World Drug Products Did Not Increase Immunogenicity in In Vivo and In Vitro Model Systems.

M. Joubert, L. Narhi, N. Joh, 2019, Journal of pharmaceutical sciences.

Quantitative measurement of the requirement of diverse protein degradation pathways in MHC class I peptide presentation

David J. Sherman, Jennifer L Mamrosh, Michael J. Sweredoski, 2023, Science advances.

Zinc binding drives sheet formation by the SAM domain of diacylglycerol kinase δ.

J. Bowie, S. Merchant, M. Joubert, 2010, Biochemistry.

A modeled structure of an aptamer-gp120 complex provides insight into the mechanism of HIV-1 neutralization.

M. Joubert, A. Capovilla, M. Khati, 2010, Biochemistry.

Immunogenicity of Therapeutic Protein Aggregates.

M. Joubert, L. Narhi, E. Topp, 2016, Journal of pharmaceutical sciences.

Chemical Modifications in Therapeutic Protein Aggregates Generated under Different Stress Conditions

Randal R Ketchem, Q. Luo, M. Joubert, 2011, The Journal of Biological Chemistry.

A High Threshold of Biotherapeutic Aggregate Numbers is Needed to Induce an Immunogenic Response In Vitro, In Vivo, and in the Clinic.

S. Brych, M. Joubert, J. Wypych, 2024, Pharmaceutical research.